SavedAdd your journal

Journals / Journal of the Turkish-German Gynecological Association / 2007 / Cilt: 8 - Sayı: 1

Postmenopozal kadınlarda hormon tedavileri sırasında lipid profili değişimi

Lipid profile changes during different hormone therapy regimens in postmenopausal women

Hüseyin Mete TANIR
Cengiz BAL
Başar TEKİN
Salih KAHRAMAN
Tufan ÖGE
Hikmet HASSA
Tanser ŞENSES
Pages
17–21
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

RESULTS: Total cholesterol decreased significantly only in E2/NETA group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: To compare the effects of hormone therapy on serum lipids in postmenopausal women.
📊
Key Findings & Data:Study Design: A retrospective study in 173 healthy postmenopausal women enrolled for this study.
💡
Conclusion & Impact:RESULTS: Total cholesterol decreased significantly only in E2/NETA group (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: To compare the effects of hormone therapy on serum lipids in postmenopausal women. Study Design: A retrospective study in 173 healthy postmenopausal women enrolled for this study. Participants had received 2 mg 17 β estradiol (E2) and 1 mg norethisterone acetate (E2/NETA) (n=21), 0.625 mg conjugated equine estrogen (CEE) and 2.5 mg medroxyprogesterone acetate (MPA) (n=38), 0.625 mg conjugated equine estrogen and 5 mg medroxyprogesterone acetate (n=39) and 2.5 mg tibolone (n=75). From the medical records, fasting serum lipid samples were evaluated before and after 6 months of treatment. RESULTS: Total cholesterol decreased significantly only in E2/NETA group (p

Özet

MAÇ: Postmenopozal kadınlarda hormon tedavisinin serum lipitleri üzerine olan etkilerini karşılaştırmak. MATERYAL METOD: Yüzyetmişüç sağlıklı postmenopozal kadın retrospektif çalışmaya dahil edildi. Katılımcılara 2 mg 17 β östrodiol ve 1 mg norethisteron asetat (E2/NETA) (n=21), 0.625 mg konjuge östrojen (CEE) ve 2.5 mg mekroksiprogesteron asetat (MPA) (n=38), 0.625 mg konjuge östrojen ve 5 mg mekroksiprogesteron asetat (n=39) ve 2.5 mg tibolon (n=75) verilerek tedavi öncesi ve 6 ay sonra serum lipit örnekleri dosya kayıtlarından değerlendirildi. BULGULAR: Sadece E2/NETA alan grupta total kolesterolde anlamlı düşüş saptandı (p

🔖

Cite This Article

TANIR, H. M., BAL, C., TEKİN, B., KAHRAMAN, S., ÖGE, T., HASSA, H., ŞENSES, T. (2022). Postmenopozal kadınlarda hormon tedavileri sırasında lipid profili değişimi. Journal of the Turkish-German Gynecological Association, Cilt: 8 - Sayı: 1, 17–21. https://ajindex.com/articles/567971

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Wild RA. Estrogens: effects on the cardiovascular tree. Obstet Gynecol 1996;87:27-35
  2. Kessler CM, Szymanski LM, Shamsipour Z et al. Estrogen replacement therapy and coagulation relationship to lipid and lipoprotein changes. Obstet Gynecol 1997;8:326-31
  3. Bass KM, Newschaffer CJ, Bush TL. Plasma lipoprotein levels as a predictor of cardiovascular death in women. Arch Intern Med 1993;153:2209-16
  4. Watts NB, Notelovitz M, Timmons MC et al. Comparisons of oral estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol 1995;85:529-37
  5. Modelska K, Cummings S. Tibolone for postmenopausal women: Systemic review of randomized trials. J Clin Endocrinol Metab 2002;87:16-23
  6. Von Eckardstein A, Crook D, Elbers J et al. Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux. Clin Endocrinol 2003;58:49-58
  7. Godsland F. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: Analysis of studies published from 1974-2000. Fertil Steril 2001;75:898-915
  8. Grodstein F, Manson JE, Colditz GA et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-41
  9. Hulley S, Grady D, Bush T et al. Heart and Estrogen/Progestin Replacement Study Research Group, Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13
  10. Grady D, Herrington D, Bittner V et al. HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002;288:49-57
  11. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 2002;288:321-33
  12. Sprecher DL. Triglycerides as a risk factor for coronary artery disease. Am J Cardiol 1998;82:49-56
  13. Prelevic GM, Kwong P, Byrne DJ et al. A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 2002;77:945-51
  14. Gokmen O, Yapar Eyi EG. Hormone replacement therapy and lipid-lipoprotein concent